Quest Diagnostics Inc  

(Public, NYSE:DGX)   Watch this stock  
Find more results for DGX
61.15
+0.35 (0.58%)
Real-time:   11:40AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 60.83 - 61.16
52 week 53.25 - 64.87
Open 60.94
Vol / Avg. 295,572.00/1.56M
Mkt cap 9.66B
P/E 16.67
Div/yield 0.30/1.96
EPS 3.67
Shares 158.03M
Beta 0.61
Inst. own 96%
Jul 15, 2013
Q2 2013 Quest Diagnostics Earnings Release Add to calendar
May 21, 2013
Quest Diagnostics Annual Stockholders Meeting
May 15, 2013
Quest Diagnostics at Bank of America Merrill Lynch Health Care Conference - Webcast
Apr 17, 2013
Q1 2013 Quest Diagnostics Earnings Conference Call - Webcast
Apr 15, 2013
Q1 2013 Quest Diagnostics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 6.90% 9.03%
Operating margin 12.71% 16.27%
EBITD margin - 21.63%
Return on average assets 5.32% 7.17%
Return on average equity 11.04% 15.98%
Employees 41,000 -
Carbon Disclosure Rating - 56/100

Address

3 Giralda Farms
MADISON, NJ 07940
United States - Map
+1-201-3935000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.

Officers and directors

Stephen H. Rusckowski President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Robert A. Hagemann Senior Vice President, Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Michael E. Prevoznik Senior Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Jon Roger Cohen M.D. Senior Vice President, Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Everett V. Cunningham Senior Vice President - Commercial
Age: 46
Bio & Compensation  - Reuters
Jim Davis Senior Vice President - Diagnostic Solutions
Bio & Compensation  - Reuters
Catherine T. Doherty Senior Vice President - Clinical Franchises
Age: 50
Bio & Compensation  - Reuters
John B. Haydon Senior Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Daniel C. Stanzione Ph.D. Non-Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
John C. Baldwin M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters